In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews (04/2011)

Executive Summary

A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Advancing the Technological Frontier in AAA Repair," features profiles of Altura Medical, Aptus Endosystems, Endoluminal Sciences and SOVAmed. Plus these Start-Ups Across Health Care: ACT Biotech, Ausio Pharmaceuticals, CureFAKtor Pharmaceuticals, Harbor MedTech and Insituvue.

You may also be interested in...

Aptus Endosystems Inc.

Despite notable advances in endovascular aortic aneurysm repair systems to prevent aneurysm rupture by stent-graft implantation, between 15-20% of patients eventually require secondary intervention to address endograft failures. Aptus Endosystems hopes to dramatically reduce the incidence of secondary intervention with its EVAR system: a low-profile modular endograft which uses novel stapling fixation that the company says approaches the durability of open surgery and makes minimally invasive AAA treatment an option for more patients, even those with challenging anatomy.

Insituvue Inc.

Clinicians could soon have "x-ray" vision when inserting a needle for vascular access. Current hand-carried ultrasound units and large cart-based systems cause hand/eye coordination problems because the surgeon needs to glance at a monitor physically located away from the patient. However, the Sonic Flashlight ultrasound device from Insituvue allows the clinician to view the ultrasonic image seemingly on the patient's skin at the point of procedure. The start-up believes its point-and-shoot technology will provide a much higher accuracy rate for a first-time stick.

Harbor MedTech Inc.

Rising rates of obesity and diabetes, coupled with America's aging population, have accelerated the demand for chronic wound care products to treat such prevalent conditions as diabetic foot ulcers, venous ulcers and pressure ulcers. To capitalize on this growing market, Harbor MedTech Inc. has developed NeuvoCell, the first candidate from its promising collagen cross-linking technology. Once inserted into the wound, NeuvoCell restarts and supports the healing process from start to finish. The xenograft also contains agents to prevent infections.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts